Erratum: Yttrium 90 ibritumomab tiuxetan in lymphoma (Leukemia & Lymphoma (2006) vol. 47 (967-977))

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1719-1720

  Cheung, M C ^a   Haynes, A E ^a   Stevens, A ^a   Meyer, R M ^a   Imrie, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL;

EID: 33748545612     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600950291     Document Type: Erratum

References (43)

1. Armitage, J and Weisenburger, D. (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol, 16, pp. 2780-2795.
2. Horning, S. (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol, 20, pp. 75-88.
3. McLaughlin, P and Grillo-Lopez, A and Link, B and Levy, R and Czuczman, M and Williams, M and (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program J Clin Oncol, 16, pp. 2825-2833.
4. Cartron, G and Watier, H and Golay, J and Solal-Celigny, P. (2004) From the bench to the bedside: Ways to improve rituximab efficacy Blood, 104, pp. 2635-2642.
5. Cheson, B. (2003) Radioimmunotherapy of non-Hodgkin lymphomas Blood, 101, pp. 391-398.
6. Browman, G and Levine, M and Mohide, E and Hayward, R and Pritchard, K and Gafni, A and (1995) The practice guidelines development cycle: A conceptual tool for practice guidelines development and implantation J Clin Oncol, 13, pp. 502-512.
7. Witzig, T and White, C and Wiseman, G and Gordon, L and Emmanouilides, C and Raubitschek, A and (1999) Phase I/II trial of IDEC - Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma J Clin Oncol, 17, pp. 3793-3803.
8. 90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) [abstract] Blood, 104(11), pp. A897.
9. Fung, H and Forman, S and Nademanee, A and Molina, A and Yamauchi, D and Speilberger, R and (2003) A new preparative regimen for older patients with aggressive CD 20-positive B-cell lymphoma utilizing standard-dose Yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): Targeted intensification without increased transplant-related toxicity [abstract] Blood, 102(11), pp. A870.
10. Forero-Torres, A and Besh, S and Knox, S and Micallef, I and Wiseman, G and Witzig, T and (2003) Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20+ B-cell follicular/transformed non-Hodgkin's lymphoma [abstract] Blood, 102(11), pp. A1483.
11. 90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma [abstract] Blood, 104(11), pp. A2633.
12. Tsimberidou, A and Murray, J and O'Brien, S and Wierda, W and Keating, M. (2004) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter Syndrome Cancer, 100, pp. 2195-2200.
13. Witzig, T and Gordon, L and Cabanillas, F and Czuczman, M and Emmanouilides, C and Joyce, R and (2002) Randomized controlled trial of Yttrium-90 - labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol, 20, pp. 2453-2463.
14. Witzig, T and Flinn, I and Gordon, L and Emmanouilides, C and Czuczman, M and Saleh, M and (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol, 20, pp. 3262-3269.
15. Wiseman, G and Gordon, L and Multani, P and Witzig, T and Spies, S and Bartlett, N and (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial Blood, 99, pp. 4336-4342.
16. Knox, S and Goris, M and Trisler, K and Negrin, R and Davis, T and Liles, T and (1996) Yttrium-90-labelled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin Cancer Res, 2, pp. 457-470.
17. Morschhauser, F and Huglo, D and Martinelli, G and Paganelli, G and Zinzani, P and Hadjiyiannakis, D and (2004) Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial [abstract] Blood, 104(11), pp. A130.
18. Oki, Y and Pro, B and Delpassand, E and Ballaster, V and McLaughlin, P and Romaguera, J and (2004) A phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract] Blood, 104(11), pp. A2632.
19. Radford, J and Ketterer, N and Sebban, C and Zinzani, P and Delaloye, A and Rohatiner, A and (2003) Ibritumomab tiuxetan (Zevalin™) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: Interim analysis for safety of a multicenter, phase III clinical trail [abstract] Blood, 102(11), pp. A1484.
20. Liu, N and Keating, M and Albitar, M and Wierda, W and Ferrajoli, A and Tran, N and (2003) Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL [abstract] Blood, 102(11), pp. A2498.
21. 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial [abstract] J Clin Oncol, 22(14 Suppl), pp. A6519.
22. Witzig, T and Wiseman, G and Geyer, S and Cripe, L and Inwards, D and Micallef, I and (2003) A phase I trial of two-sequential doses of Zevalin™ radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma [abstract] Blood, 102(11), pp. A1475.
23. 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses higher than 0.4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: The role for dosimetry [abstract] Blood, 104(11), pp. A1162.
24. 90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial [abstract] J Clin Oncol, 22(14 Suppl), pp. A6504.
25. Vose, J and Bierman, P and Lynch, J and Bociek, G and Multani, P and Armitage, J. (2003) Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT) [abstract] Blood, 102(11), pp. A92.
26. 90Y) ibritumomab tiuxetan (Zevalin) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT) [abstract] Blood, 104(11), pp. A5238.
27. Gordon, L and Witzig, T and Molina, A and Czuczman, M and Emmanouilides, C and Joyce, R and (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma Clin Lymphoma, 5(2), pp. 98-101.
28. Gordon, L and Witzig, T and Murray, J and Czuczman, M and Emmanouilides, C and Joyce, R and (2003) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: Final results of a randomized controlled trial [abstract] Proc Am Soc Clin Oncol, 22(576), pp. A2315.
29. Wiseman, G and Witzig, T and Murray, J and Podoloff, D and Gordon, L and Schilder, R and (2000) Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade, follicular, or transformed non-Hodgkin's lymphoma (LG/F/T NHL) [abstract] Blood, 96(11), pp. A3173.
30. Schilder, R and Molina, A and Bartlett, N and Witzig, T and Gordon, L and Murray, J and (2004) Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia Cancer Biother Radiopharm, 19, pp. 478-481.
31. Emmanouilides, C and Czuczman, M and Revell, S and Witzig, T and Wang, H and Gordon, L and (2004) Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan [abstract] J Clin Oncol, 22(14 Suppl), pp. A6696.
32. Witzig, T and Gordon, L and Wiseman, G and Spies, S and Emmanouilides, C and Czuczman, M and (2000) Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) [abstract] Blood, 96(11), pp. A3160.
33. Witzig, T and White, C and Gordon, L and Wiseman, G and Emmanouilides, C and Murray, J and (2001) Zevalin™ radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) [abstract] Blood, 98(11), pp. A2539.
34. Witzig, T and White, C and Gordon, L and Wiseman, G and Emmanouilides, C and Murray, J and (2003) Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma J Clin Oncol, 21, pp. 1263-1270.
35. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients [abstract] Proc Am Soc Clin Oncol, 21(14a), pp. A51.
36. Emmanouilides, C and Murray, J and Vo, K and Witzig, T and Darif, M and Schilder, R and (2003) Earlier treatment with Yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): Results with second-line therapy [abstract] Blood, 102(11), pp. A4949.
37. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma [abstract] Proc Am Soc Clin Oncol, 21(266a), pp. A1062.
38. Gibson, A. (2002) Updated results of a phase III trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma Clin Lymphoma, 3, pp. 87-89.
39. Nabhan, C and Peterson, L and Kent, S and Tallman, M and Dewald, G and Multani, P and (2002) Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma Leuk Lymphoma, 43, pp. 2145-2149.
40. Schilder, R and Witzig, T and Gordon, L and Wiseman, G and Murray, J and Bartlett, N and (2001) Zevalin radioimmunotherapy (RIT) for low grade, follicular, and Cd20+ transformed non-Hodgkin's lymphoma (LG/F/T NHL) is effective even in patients with mild thrombocytopenia and poor prognostic factors [abstract] Proc Am Soc Clin Oncol, 20(236b), pp. A2696.
41. Wiseman, G and Leigh, B and Dunn, W and Stabin, M and White, C. (2003) Additional radiation absorbed dose estimates for Zevalin™ radioimmunotherapy Cancer Biother Radiopharm, 18, pp. 253-258.
42. Wiseman, G and White, C and Sparks, R and Erwin, W and Podoloff, D and Lamonica, D and (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trail of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Crit Rev Oncol Hematol, 39, pp. 181-194.
43. 90 Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy: Results from a Zevalin imaging registry [abstract] Blood, 104(11), pp. A4570.